About the company

GlycoTherapeutics is a drug development startup committed to overcome the efficacy limitations of current cancer immunotherapies. Less than 50% of individuals with cancer receiving immunotherapy obtain a durable response, which is partly due to glycobiology processes that suppress the immune system. Based on over a decade of research, GlycoTherapeutics’ proprietary solution targets these processes by disrupting the interaction of glycans (sugars) that are responsible for immune evasion. The company was established in 2022 as a spin-off from Radboud University, Nijmegen in the Netherlands and has raised >€1.5 million in non-dilutive funding.

Founding team

Events & News

Meet us at these events:

Other news:

Contact us

Please contact us by mail johan.pijnenborg@glycotherapeutics.eu or give us a call on +316 53182635.

Keep up to date